araag2/HINT huggingface dataset:
Clinical trial NCT01225315 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: placebo, setipiprant
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  Males and females age 18 to 65 years

          -  Women of childbearing potential must use adequate contraception

          -  Presenting with a diagnosis of asthma according to GINA Guidelines

          -  Pre-bronchodilator forced expiratory volume in one second (FEV1) < / = 85% of
             patient's predicted normal value

          -  Reversibility of airway obstruction of > / = 12% and > / = 200mL from
             pre-bronchodilator FEV1

          -  ACQ score > / = 1.5

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Any asthma exacerbation requiring treatment with systemic corticosteroids within the
             last 3 months

          -  Ongoing or recent treatment with medication for allergic airway disease

          -  Smoking within the last year, or life-time consumption > / = 10 pack-years (e.g., 20
             cigarettes/day for 10 years)

          -  History of chronic pulmonary disease (other than asthma), such as chronic obstructive
             pulmonary disease (COPD), fibrosis, tuberculosis or sarcoidosis

          -  Pregnant or lactating women

          -  Diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma

          -  Any hospital admission for asthma within the last 6 months

          -  Anti-IgE therapy at any time check/update interventions by explicitely writing the
             experimental drug dosage in the interventions description

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
Clinical trial NCT00035529 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: placebo, bms 188667 (abatacept), bms 188667 (abatacept)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion

          -  relapsing-remitting MS

          -  at least 1 exacerbation in preceding 2 years

          -  at least 1 MRI lesion

          -  stable for 2 months prior to dosing

        Exclusion

          -  progressive MS

          -  currently treated with an immunomodulatory therapy

          -  previously treated with an approved MS drug where treatment was discontinued for lack
             of efficacy

          -  active bacterial or viral infections
Clinical trial NCT00322491 (phase 2, status: completed)
Conditions: lymphoma, non-hodgkin, multiple myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00
Drugs: g-csf plus plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for
             autologous transplantation

          -  No more than 3 prior regimens of chemotherapy

          -  More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute
             toxic effects of prior chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  White blood cell (WBC) count >3.0*10^9/L

          -  Absolute polymorphonuclear cells (PMN) count >1.5*10^9/L

          -  Platelet (PLT) count >100*10^9/L

          -  Serum creatinine <=2.2 mg/dL

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) and total bilirubin <2 x upper limit of normal (ULN)

          -  Left ventricle ejection fraction >45% by normal echocardiogram or multiple-gated
             acquisition (MUGA) scan

          -  Forced expiratory volume of the lung in the first second (FEV1) >60% of predicted or
             diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted

          -  Negative for human immunodeficiency virus (HIV) type 1

          -  Women of child bearing potential agreed to use an approved form of contraception.

        Exclusion Criteria:

          -  Patients who have failed previous collections

          -  Brain metastases or carcinomatous meningitis

          -  History of ventricular arrhythmias

          -  A co-morbid condition which, in the view of the investigator, renders the patient at
             high risk for treatment complications

          -  A residual acute medical condition resulting from prior chemotherapy

          -  Acute infection

          -  Fever (temp >38°C/100.4°F)

          -  Patients whose actual body weight exceeds 175% of their ideal body weight

          -  Patients who previously received experimental therapy within 4 weeks of enrolling in
             this study or who are currently enrolled in another experimental study during the
             mobilization period

          -  Positive pregnancy test in female patients

          -  Lactating females

          -  Patients of child-bearing potential unwilling to implement adequate birth control.

          -  Patients who have deterioration of their clinical status or laboratory parameters
             between the time of enrolment and transplant (such that they no longer meet entry
             criteria) may be removed from study at the discretion of the treating physician,
             principal investigator, or sponsor.
Clinical trial NCT00112658 (phase 2/phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  No other pancreatic tumor type, including either of the following:

                    -  Neuroendocrine tumor

                    -  Acinar cell tumor

               -  Metastatic disease

          -  Measurable disease in an area not previously irradiated

          -  No cerebral metastases or meningeal involvement of the tumor

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 75

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)

        Renal

          -  Creatinine < 120 mmol/L

        Cardiovascular

          -  No prior myocardial infarction

          -  No prior angina

          -  No uncompensated cardiac or coronary insufficiency

          -  No symptomatic arrhythmia

        Gastrointestinal

          -  No prior inflammatory bowel disease

          -  No prior chronic diarrhea

          -  No unresolved symptomatic occlusion or subocclusion of the bowel

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No ongoing active infection

          -  No other malignancy except basal cell or squamous cell skin cancer or carcinoma in
             situ of the cervix

          -  No contraindication to study treatment

          -  No other serious medical disorder that would preclude study treatment

          -  No psychiatric disorder or social or geographic situation that would preclude study
             participation

          -  Not detained or under the guardianship of another person

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in another clinical trial using therapeutic experimental
             agents
Clinical trial NCT00281970 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologically proven non-small cell lung cancer (NSCLC)

               -  Stage IA-IIIB disease

          -  Underwent prior complete surgical resection (R0) no more than 2 months ago

          -  Eligible for cisplatin-based adjuvant chemotherapy

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status ≥ 70%

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine clearance > 55 mL/min

          -  Total bilirubin normal

          -  Alkaline phosphatase, AST, and ALT must meet 1 of the following criteria:

               -  Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit of normal
                  (ULN)

               -  AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN

               -  AP ≤ 5 times ULN AND AST and ALT normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
             with polysorbate 80

          -  No peripheral neuropathy > grade 1

          -  No hearing deficit at baseline, even if it does not require a hearing aid or
             intervention or interfere with activities of daily life (i.e., CTCAE grade 2 or
             higher)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior postoperative radiation therapy

          -  No prior chemotherapy for NSCLC

          -  No prior docetaxel or cisplatin

          -  No concurrent prophylactic filgrastim (G-CSF) or pegfilgrastim
Clinical trial NCT00619619 (phase 2, status: completed)
Conditions: depression, major depressive disorder
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: desvenlafaxine succinate sustained-release tablets (dvs sr)
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatient between 7 and 17 years of age at baseline who meet
             Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision
             criteria for major depressive disorder.

          -  Children's Depression Rating Scale --Revised (CDRS-R) score greater than 40 at the
             screening and study day -1 (baseline) visits and Clinical Global Impressions
             Scale--Severity (CGI-S) score of greater than or equal to 4 at the screening and study
             day -1 (baseline) visits.

          -  Depression of at least moderate severity with symptoms for at least 1 month before
             screening and that could, in the investigator's opinion, respond to therapy with
             antidepressant(s) alone (without concomitant psychotherapy).

          -  Other inclusion criteria apply.

        Exclusion Criteria:

          -  History or current evidence of a medical condition known to interfere with the
             absorption or excretion of drugs or a history of surgery known to interfere with the
             absorption or excretion of drugs; history or presence of any other medical condition
             that might confound the study or put the study participant at greater risk during
             participation; known hypersensitivity to venlafaxine.

          -  History of suicide attempt or gesture in which the intent was suicide or serious
             self-harm or acute suicidality to such a degree that precaution against suicide must
             be exercised.

          -  Current (within 12 months before baseline) psychoactive substance abuse or dependence
             (including alcohol), manic episode, posttraumatic stress disorder,
             obsessive-compulsive disorder, or a diagnosis of bipolar disorder or psychotic
             disorder or current (within 12 months before baseline) generalized anxiety disorder,
             panic disorder, social anxiety disorder, or attention deficit hyperactivity disorder
             (ADHD) if considered by the investigator to be primary (causing a higher degree of
             distress or impairment than MDD) or presence (within 12 months before baseline) of a
             clinically important personality disorder (such as antisocial, schizotypal,
             histrionic, borderline, or narcissistic) as assessed during the psychiatric
             evaluations or history or presence of MDD with psychotic features.

          -  Other exclusion criteria apply.
Clinical trial NCT01370031 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: clenil® modulite® via aerochamber plus™, clenil® modulite® via volumatic™ spacer, clenil® modulite® via aerochamber plus™ plus charcoal block, clenil® modulite® administered via volumatic™ spacer plus charcoal block
SMILES: [C], [C]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant female patients aged 18-65 years included.

          -  Diagnosis of asthma according to GINA guidelines 2009 made at least 6 months prior to
             screening.

          -  Patients already treated with a dose of BDP or equivalent up to 2000 µg/day.

          -  FEV1 ≥ 60% of predicted for the patient's normal value at screening and randomisation

        Exclusion Criteria:

          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12
             weeks for parenteral depot corticosteroids) before screening visit.

          -  Exacerbation of asthma symptoms or hospitalization due to asthma exacerbation within
             the previous one month before screening until randomisation.

          -  Lower respiratory tract infection within one month prior to screening.

          -  Diagnosis of COPD as defined by the current GOLD 2009 (Global Initiative for Chronic
             Obstructive Lung Disease) Guidelines.

          -  Significant medical history and/or treatments for cardiac, renal, neurological,
             hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant
             underlying condition, that may interfere with patient's safety, compliance, or study
             evaluations, according to the Investigator's opinion.

          -  Treatment with a xanthine derivative (e.g. theophylline) formulation in the 4 weeks
             prior to screening.

          -  Any enzyme inducing or inhibiting drug (from 8 weeks before screening visit)

          -  Patients who received any investigational new drug within the last 8 weeks before the
             screening. The patients cannot participate in another clinical study at the same time
             as the present study.

          -  Blood donation (450 mL or more)or significant blood loss less than 12 weeks before the
             first intake of study drug.
Clinical trial NCT01375179 (phase 2, status: terminated)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: krp203, placebo matching krp203
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Active disease defined by partial Mayo score and modified Baron score with disease
             extending at least 25 cm from the anal verge

          -  Subjects must have inadequately responded or intolerance to 5-ASA therapy

        Exclusion Criteria:

          -  Subjects receiving treatment for UC (other than 5-ASAs and steroids) within the time
             frame mentioned in protocol

          -  Past or recent history of significant medical illness and/or clinically significant
             lab abnormalities including but not limited to hematology, clinical chemistry, urine
             analysis, ECG abnormalities, HIV, Hepatitis B/C

          -  Presence or history of underlying metabolic, endocrine, hematologic, pulmonary,
             ophthalmic, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically
             unstable condition, as assessed by the primary treating physician which, in the
             opinion of the investigator, would immunocompromise the subject and/or place the
             subject at unacceptable risk for participation in a study of an immunomodulatory
             therapy Other protocol-defined inclusion/exclusion criteria apply
Clinical trial NCT01493479 (phase 2, status: completed)
Conditions: follicular lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: 90y ibritumomab tiuxetan, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a histologically confirmed CD20 +ve follicular lymphoma grades I to
             IIIa.

          -  Patients with at least one of the following symptoms requiring initiation of
             treatment: (as outlined by the modified BNLI/GELF criteria below)

               -  Nodal mass > 7cm in its greater diameter

               -  B symptoms

               -  Elevated serum LDH or beta2-microglobulin

               -  involvement of at least 3 nodal sites (each with a diameter > 3 cm)

               -  symptomatic splenic enlargement

               -  compressive syndrome

          -  Patients must have an ECOG performance status less than or equal to 2 and an
             anticipated survival of at least 6 months.

          -  Patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet
             count of above 100,000/mm3 post 4 weeks of unlabelled Rituximab. A hemoglobin >= 8.0
             g/dl

          -  Patients must have adequate renal function (defined as calculated creatinine clearance
             > 30 ml/mn), hepatic function (defined as total bilirubin <1.5 times upper limit of
             normal), and hepatic transaminases (defined as AST <5 times upper limit of normal)

          -  Patients must have given informed consent prior to study entry.

        Exclusion Criteria:

          -  Patients with a mean of >20% of the intratrabecular marrow space involved with
             lymphoma on bone marrow biopsy following induction Rituximab therapy.

          -  Transformed follicular lymphoma and discordant lymphoma

          -  Patients with active obstructive hydronephrosis.

          -  Patients with initial disease bulk greater than 10cm.

          -  Patients with evidence of active infection requiring i.v. antibiotics at the time of
             study entry.

          -  Patients with congestive heart failure stage III or IV of NYHA classification,
             myocardial infraction or unstable angina within 6 months or other serious illness that
             would preclude evaluation.

          -  Patients with left VEF < 40%

          -  Patients with large pleural or peritoneal effusions.

          -  Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.

          -  Known Hypersensitivity to murine antibodies or proteins

          -  Patients who are pregnant or breast-feeding. Male and female patients must agree to
             use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody
             therapy.

          -  Patients with prior malignancy other than lymphoma, except for adequately-treated skin
             cancer, cervical cancer in situ, or other cancer for which the patient has been
             disease-free for 5 years.
Clinical trial NCT00774878 (phase 2, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ave1642, fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Reason stopped: 
    company decision to discontinue the ave1642 development program, not due to any safety or
    efficacy concerns
  
Eligibility criteria:

        Inclusion Criteria:

          -  Post-menopausal women

          -  Aromatase inhibitor as the last hormonal treatment

          -  Breast adenocarcinoma with positive hormone receptor

          -  Measurable disease as per RECIST definition

        Exclusion Criteria:

          -  ECOG performance status (PS) > 2

          -  Prior exposure to fulvestrant or to an anti IGF-1R compound

          -  No evidence of hormonosensitivity

          -  HER 2-neu positive tumor

          -  More than one prior regimen of chemotherapy for metastatic disease

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01469377 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, cariprazine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients 18 to 65 years of age, inclusive.

          -  Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR) criteria for moderate to severe major depressive
             disorder (MDD).

          -  Current major depressive episode of at least 8 weeks and not exceeding 24 months in
             duration.

          -  Ongoing inadequate response to protocol allowed antidepressant therapy (ADT).

        Exclusion Criteria:

          -  Principal DSM-IV-TR-based diagnosis of an axis I disorder, other than MDD,

          -  Women who are pregnant, or planning to become pregnant or breastfeed during the study
             or not practicing reliable contraception that will continue through out the study.

          -  History of meeting DSM-IV-TR criteria for:

               1. Depressive episode with psychotic or catatonic features.

               2. Manic, hypomanic or mixed episode, including bipolar disorder and substance
                  induced manic, hypomanic or mixed episode.

               3. Schizophrenia, schizoaffective, or other psychotic disorder.

               4. Obsessive-compulsive disorder.

               5. Bulimia or anorexia nervosa.

               6. Dementia, amnesic, or other cognitive disorder.

               7. Mental retardation.

          -  Participants considered a suicide risk.